The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

THP combines one chemotherapy drug (a taxane) with the HER2-targeting drugs trastuzumab and pertuzumab. THP is a standard treatment for patients with metastatic HER2+ breast cancer. Previous small ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...